A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)

NCT01241552 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1452

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection

Interventions

BIOLOGICAL: MK-3415
BIOLOGICAL: MK-6072
BIOLOGICAL: MK-3415A
BIOLOGICAL: Placebo
DRUG: SOC

Sponsor

Merck Sharp & Dohme LLC